gdc
FDA NewsNewsworthy

Actemra First Treatment Approved for CAR T-Cell–Induced Cytokine-Release Syndrome


December 2017 Vol 3 No 6 – December 18, 2017

On August 30, 2017, in association with the approval of the first CAR T-cell therapy (Kymriah), the FDA approved a new use for Actemra (tocilizumab; from Genentech), a humanized IL-6 receptor antagonist, for CAR T-cell–induced severe or life-threatening cytokine-release syndrome in patients older than 2. Cytokine-release syndrome can be caused by immune-cell therapy, such as CAR T-cell therapy.

This approval was based on a clinical trial showing the benefits of Actemra in patients with cytokine-release syndrome. Overall, 69% of patients had a response to Actemra within 14 days of treatment, meaning that the cytokine-release syndrome was resolved.

Serious side effects with Actemra include risk of serious infections and certain cancers, tears in the stomach, thrombocytopenia, neutropenia, hepatitis B infection, serious allergic reactions, and central nervous system problems.

Recommended For You
Cancer ScreeningFDA NewsNewsworthy
FDA Approves First Direct-to-Consumer Genetic Test for 3 Types of BRCA Mutations in Men and Women
By Dana Taylor
This first-ever direct-to-consumer genetic test can provide information on potential risks to individuals who may not have access to genetic screening, but the information may be misleading without feedback from experts.
LeukemiaNewsworthyWeb Exclusives
Quizartinib Significantly Improves Survival Over Chemotherapy in Patients with Relapsed/Refractory AML and FLT3-ITD Mutation
This is the first treatment that targets patients with AML and the FLT3-ITD mutation. In this clinical trial, patients who received quizartinib lived longer without disease progression than those receiving chemotherapy.
Breast CancerNewsworthy
Living Beyond Breast Cancer to Host 12th Annual National Metastatic Breast Cancer Conference in Philadelphia, April 20-22
Hundreds of people with metastatic breast cancer and their caregivers from across the country will attend the 2018 Conference on Metastatic Breast Cancer in Philadelphia on April 20–22, 2018, hosted by Living Beyond Breast Cancer.
Last modified: January 2, 2018

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.

Country